Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome)

Nephrology Dialysis Transplantation

Volumn 23, Issue 8, 2008, Pages 2690-2692

  Pecci, Alessandro ^a,c   Granata, Antonio ^b,c   Fiore, Carmelo E ^b,c   Balduini, Carlo L ^a,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Italian Registry for MYH9 Related Disease ^*  (Italy)

Author keywords

Fechtner syndrome; MYH9 related disease; Renin angiotensin system blockade

Indexed keywords

LOSARTAN; MYOSIN HEAVY CHAIN; PROTEIN MHY9; RAMIPRIL; TELMISARTAN;

ADULT; ANAMNESIS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; CLINICAL EXAMINATION; FECHTNER EPSTEIN SYNDROME; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CATARACT; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; KIDNEY DISEASES; LOSARTAN; MALE; MOLECULAR MOTOR PROTEINS; MUTATION; MYOSIN HEAVY CHAINS; PROTEINURIA; RAMIPRIL; RENIN-ANGIOTENSIN SYSTEM; SYNDROME; THROMBOCYTOPENIA;

EID: 48749118166     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn277     Document Type: Article

References (13)

1. Rocca B, Laghi F, Zini G et al. Fechtner syndrome: report of a third family and literature review. Br J Haematol 1993; 85: 423-426
2. Epstein CJ, Sahud MA, Piel CF et al. Hereditary macrothrombocytopenia, nephritis and deafness. Am J Med 1972; 75: 299-310
3. Seri M, Cusano R, Gangarossa S et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner syndrome consortium. Nat Genet 2000; 26: 103-105
4. Arrondel C, Vodovar N, Knebelmann B et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 2002; 13: 65-74
5. Seri M, Pecci A, Di Bari F et al. MYH9-related disease: May Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82: 203-215
6. Pecci A, Panza E, Pujol-Moix N et al. Position of nonmuscle myosin IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29: 409-417
7. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124
8. Jafar TH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140
9. Proesmans W, Van Dick M. Enalapril in children with Alport syndrome. Pediatr Nephrol 2004; 19: 271-275
10. Gross O, Beirowski B, Keopke ML et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003; 63: 438-446
11. Ghiggeri GM, Caridi G, Magrini U et al. Genetics, clinical and pathological features of glomerulonephrites associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis 2003; 41: 95-104
12. Canobbio I, Noris P, Pecci A et al. Altered cytoskeleton organization in platelets from patients with MYH9-related disease. J Thromb Haemost 2005; 3: 1026-1035
13. Reiser J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007; 9: 403-408